Alnylam Pharmaceuticals (ALNY) Work In Process (2018 - 2026)

Alnylam Pharmaceuticals (ALNY) has 9 years of Work In Process data on file, last reported at $65.5 million in Q1 2026.

• For the quarter ending Q1 2026, Work In Process rose 21.24% year-over-year to $65.5 million; the trailing twelve-month figure through Mar 2026 stood at $65.5 million (up 21.24% YoY), and the FY2025 full-year result was $65.1 million, changed 0.22% from the prior year.
• Work In Process for Q1 2026 stood at $65.5 million, up from $65.1 million in the prior quarter.
• Across five years, Work In Process topped out at $116.7 million in Q2 2023 and bottomed at $35.5 million in Q3 2025.
• The 5-year median for Work In Process is $76.1 million (2024), against an average of $79.0 million.
• The widest annual swing landed in 2022, when Work In Process surged 295.84%; it then slumped 49.18% in 2025.
• A 5-year view of Work In Process shows it stood at $113.8 million in 2022, then sank by 32.36% to $77.0 million in 2023, then declined by 15.57% to $65.0 million in 2024, then increased by 0.22% to $65.1 million in 2025, then climbed by 0.51% to $65.5 million in 2026.
• The last three Work In Process figures came in at $65.5 million (Q1 2026), $65.1 million (Q4 2025), and $35.5 million (Q3 2025), per Business Quant data.

Peer Comparison